AuthorTikhomirova, Victoria E.
Kost, Olga A.
Kryukova, Olga V.
Golukhova, Elena Z.
Bulaeva, Naida I.
Zholbaeva, Aigerim Z.
Bokeria, Leo A.
Garcia, Joe G. N.
Danilov, Sergei M.
AffiliationUniv Arizona Hlth Sci
MetadataShow full item record
PublisherPUBLIC LIBRARY SCIENCE
CitationACE phenotyping in human heart 2017, 12 (8):e0181976 PLOS ONE
Rights© 2017 Tikhomirova et al. This is an open access article distributed under the terms of the Creative Commons Attribution License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at firstname.lastname@example.org.
AbstractAims Angiotensin-converting enzyme (ACE), which metabolizes many peptides and plays a key role in blood pressure regulation and vascular remodeling, is expressed as a type-1 membrane glycoprotein on the surface of different cells, including endothelial cells of the heart. We hypothesized that the local conformation and, therefore, the properties of heart ACE could differ from lung ACE due to different microenvironment in these organs. Methods and results We performed ACE phenotyping (ACE levels, conformation and kinetic characteristics) in the human heart and compared it with that in the lung. ACE activity in heart tissues was 10-15 lower than that in lung. Various ACE effectors, LMW endogenous ACE inhibitors and HMW ACE-binding partners, were shown to be present in both heart and lung tissues. "Conformational fingerprint" of heart ACE (i.e., the pattern of 17 mAbs binding to different epitopes on the ACE surface) significantly differed from that of lung ACE, which reflects differences in the local conformations of these ACEs, likely controlled by different ACE glycosylation in these organs. Substrate specificity and pH-optima of the heart and lung ACEs also differed. Moreover, even within heart the apparent ACE activities, the local ACE conformations, and the content of ACE inhibitors differ in atria and ventricles. Conclusions Significant differences in the local conformations and kinetic properties of heart and lung ACEs demonstrate tissue specificity of ACE and provide a structural base for the development of mAbs able to distinguish heart and lung ACEs as a potential blood test for predicting atrial fibrillation risk.
NoteOpen access journal.
VersionFinal published version
SponsorsMinistry of Science and Education of Russian Federation [14.Z50.31.0026]
CollectionsUA Faculty Publications
- Tissue Specificity of Human Angiotensin I-Converting Enzyme.
- Authors: Kryukova OV, Tikhomirova VE, Golukhova EZ, Evdokimov VV, Kalantarov GF, Trakht IN, Schwartz DE, Dull RO, Gusakov AV, Uporov IV, Kost OA, Danilov SM
- Issue date: 2015
- N-domain angiotensin-converting enzyme isoform expression in tissues of Wistar and spontaneously hypertensive rats.
- Authors: Ronchi FA, Andrade MC, Carmona AK, Krieger JE, Casarini DE
- Issue date: 2005 Oct
- Heterogeneous distribution of angiotensin I-converting enzyme (CD143) in the human and rat vascular systems: vessel, organ and species specificity.
- Authors: Metzger R, Franke FE, Bohle RM, Alhenc-Gelas F, Danilov SM
- Issue date: 2011 Mar
- [Studies on angiotensin I converting enzyme (ACE): inhibitory effect of imidapril, a novel ACE inhibitor (II). Inhibition of various tissue ACEs ex vivo].
- Authors: Hashimoto Y, Kubo M, Sugaya T, Minobe S, Watanabe T, Yamamura M, Matsuoka Y
- Issue date: 1994 Jul
- Conformational fingerprinting of the angiotensin I-converting enzyme (ACE). 1. Application in sarcoidosis.
- Authors: Danilov SM, Balyasnikova IV, Danilova AS, Naperova IA, Arablinskaya NE, Borisov SE, Metzger R, Franke FE, Schwartz DE, Gachok IV, Trakht IN, Kost OA, Garcia JG
- Issue date: 2010 Nov 5